Leucomethylthioninium is the reduced form of methylthioninium, also known as the reduced form of methylene blue. It has been investigated as a tau aggregation inhibitor for neurodegenerative disorders, particularly Alzheimer's disease.
Leucomethylthioninium can undergo oxidation to methylthioninium and has been studied for its potential effects on abnormal tau protein aggregation, a pathological feature associated with several neurodegenerative diseases.
Leucomethylthioninium is a specialized neurodegenerative-disease research pharmaceutical ingredient requiring controlled synthesis, purification and characterization of its chemical and redox properties.
Important quality attributes include identity, assay, related substances, redox-state characterization, water content, residual solvents, elemental impurities and stability.
CAS Number: 1231740-90-1
Molecular Formula: C16H18N3S+
Molecular Weight: 284.40 g/mol
Drug Class: Investigational Neurodegenerative Agent
Pharmacological Class: Tau Aggregation Inhibitor
Therapeutic Class: Neurodegenerative Disease Research Agent
Therapeutic Area: Neurology / Neurodegeneration
Leucomethylthioninium has been investigated for its ability to interfere with tau protein aggregation.
Tau proteins can become abnormally modified and aggregate into paired helical filaments and neurofibrillary tangles in Alzheimer's disease and other tauopathies.
Research has investigated whether leucomethylthioninium-derived species can:
Leucomethylthioninium has been investigated in research involving:
Its clinical-development history includes investigation as a potential disease-modifying approach targeting tau pathology.
Leucomethylthioninium exists in a reduced redox state and can be oxidized to methylthioninium.
This redox behavior is important when evaluating:
Therefore, appropriate analytical control of the redox state is particularly important for pharmaceutical-quality evaluation.
Typical manufacture may involve:
Leucomethylthioninium API quality evaluation may include:
Leucomethylthioninium should be stored under controlled pharmaceutical conditions with appropriate protection from oxygen, light, moisture and excessive heat, because its reduced redox state may be susceptible to oxidation.
Final storage conditions should be established through validated stability studies.
Leucomethylthioninium is relevant to research involving:
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | ≤ 0.5% |
| Total Impurities | ≤ 1.5% |
| Water Content | NMT 1.0% |